GvHD Treatment

Jul 04, 2025

The GvHD drugs treatment landscape is undergoing a dynamic transformation, driven by a wave of innovation aimed at improving patient outcomes and quality of life. Once dominated by steroids and broad immunosuppressants, the field is now witnessing a surge in targeted therapies, cellular approaches, and novel biolog...

Jun 23, 2023

Allogeneic HSCT is a mainstay for patients with different hematological malignancies, but it requires immunosuppressive strategies before and after HSCT. However, approximately half (50%) of the patients receiving allogeneic hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-matched ...